p.73 抽出テキスト
CLINICAL STATEMENTS AND GUIDELINES Circulation. 2025;151:e771–e862. DOI: 10.1161/CIR.0000000000001309 April 1, 2025 e843 agement of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082–e1143. 4.6. Beta-Blocker Therapy 1. Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebocontrolled trial. Lancet. 2005;366:1622–1632. 2. Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred betablockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation. 1991;83:422–437. 3. Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730–1737. 4. de Peuter OR, Lussana F, Peters RJ, et al. A systematic review of selective and non-selective beta blockers for prevention of vascular events in patients with acute coronary syndrome or heart failure. Neth J Med. 2009;67:284– 294. 5. Dahl Aarvik M, Sandven I, Dondo TB, et al. Effect of oral beta-blocker treatment on mortality in contemporary post-myocardial infarction patients: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2019;5:12–20. 6. Kontos MC, Diercks DB, Ho PM, et al. Treatment and outcomes in patients with myocardial infarction treated with acute beta-blocker therapy: results from the American College of Cardiology’s NCDR. Am Heart J. 2011;161:864–870. 7. Yndigegn T, Lindahl B, Mars K, et al. Beta-blockers after myocardial infarction and preserved ejection fraction. N Engl J Med. 2024;390:1372–1381. 8. Watanabe H, Ozasa N, Morimoto T, et al. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PLoS One. 2018;13:e0199347. 9. Roolvink V, Ibanez B, Ottervanger JP, et al. Early intravenous beta-blockers in patients with ST-segment elevation myocardial infarction before primary percutaneous coronary intervention. J Am Coll Cardiol. 2016;67:2705– 2715. 10. Ibanez B, Macaya C, Sanchez-Brunete V, et al. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the effect of metoprolol in cardioprotection during an acute myocardial infarction (METOCARD-CNIC) trial. Circulation. 2013;128:1495–1503. 4.7. Renin-Angiotensin-Aldosterone System Inhibitors 1. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992;327:669–677. 2. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med. 1995;332:80–85. 3. Koeber L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;333:1670– 1676. 4. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100 000 patients in randomized trials. Circulation. 1998;97:2202–2212. 5. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893–1906. 6. The Acute Infarction Ramipril Efficacy Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821–828. 7. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321. 8. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–1559. 9. McMurray JJV, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004. 10. Pfeffer MA, Claggett B, Lewis EF, et al. Angiotensin receptor-neprilysin inhibition in acute myocardial infarction. N Engl J Med. 2021;385:1845– 1855. 11. Montalescot G, Pitt B, Lopez de Sa E, et al. Early eplerenone treatment in pa- tients with acute ST-elevation myocardial infarction without heart failure: the randomized double-blind REMINDER study. Eur Heart J. 2014;35:2295– 2302. 5.1. Regional Systems of STEMI Care 1. Alexander T, Mullasari AS, Joseph G, et al. A system of care for patients with ST-segment elevation myocardial infarction in India: the Tamil Nadu- ST-Segment Elevation Myocardial Infarction Program. JAMA Cardiol. 2017;2:498–505. 2. Dharma S, Andriantoro H, Dakota I, et al. Hospital outcomes in STEMI patients after the introduction of a regional STEMI network in the metropolitan area of a developing country. AsiaIntervention. 2018;4:92–97. 3. Filgueiras Filho NM, Feitosa Filho GS, Solla DJF, et al. Implementation of a regional network for ST-segment-elevation myocardial infarction (STE- MI) care and 30-day mortality in a low- to middle-income city in Brazil: findings from Salvador’s STEMI registry (RESISST). J Am Heart Assoc. 2018;7:e008624. 4. Jollis JG, Al-Khalidi HR, Roettig ML, et al. Regional systems of care demonstration project: American Heart Association Mission: Lifeline STEMI Systems Accelerator. Circulation. 2016;134:365–374. 5. Jollis JG, Al-Khalidi HR, Roettig ML, et al. Impact of regionalization of STsegment-elevation myocardial infarction care on treatment times and outcomes for emergency medical services-transported patients presenting to hospitals with percutaneous coronary intervention: Mission: Lifeline Accelerator-2. Circulation. 2018;137:376–387. 6. Puymirat E, Simon T, Cayla G, et al. Acute myocardial infarction: changes in patient characteristics, management, and 6-month outcomes over a period of 20 years in the FAST-MI program (French Registry of Acute ST-Elevation or Non-ST-Elevation Myocardial Infarction) 1995 to 2015. Circulation. 2017;136:1908–1919. 7. Jacobs AK, Ali MJ, Best PJ, et al. Systems of care for ST-segment-elevation myocardial infarction: a policy statement from the American Heart Association. Circulation. 2021;144:e310–e327. 8. Jollis JG, Granger CB, Zegre-Hemsey JK, et al. Treatment time and in-hos- pital mortality among patients with ST-segment elevation myocardial infarction, 2018-2021. JAMA. 2022;328:2033–2040. 5.2.1 PPCI in STEMI 1. McNamara RL, Wang Y, Herrin J, et al. Effect of door-to-balloon time on mortality in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2006;47:2180–2186. 2. De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation. 2004;109:1223–1225. 3. Berger PB, Ellis SG, Holmes DR Jr, et al. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. Circulation. 1999;100:14–20. 4. Menees DS, Peterson ED, Wang Y, et al. Door-to-balloon time and mortality among patients undergoing primary PCI. N Engl J Med 2013;369:901– 909. 5. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes Angioplasty Substudy I. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997;336:1621–1628. 6. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361:13–20. 7. Zijlstra F, Hoorntje JC, de Boer MJ, et al. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med. 1999;341:1413–1419. 8. Scholz KH, Maier SKG, Maier LS, et al. Impact of treatment delay on mortality in ST-segment elevation myocardial infarction (STEMI) patients presenting with and without haemodynamic instability: results from the German prospective, multicentre FITT-STEMI trial. Eur Heart J. 2018;39:1065–1074. 9. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med. 1999;341:625–634. 10. Axelsson TA, Mennander A, Malmberg M, et al. Is emergency and salvage coronary artery bypass grafting justified? The Nordic emergency/ salvage coronary artery bypass grafting study. Eur J Cardiothorac Surg. 2016;49:1451–1456. 11. Liakopoulos OJ, Schlachtenberger G, Wendt D, et al. Early clinical outcomes of surgical myocardial revascularization for acute coronary syndromes com- Downloaded from http://ahajournals.org by on October 7, 2026